0001209191-22-042841.txt : 20220721 0001209191-22-042841.hdr.sgml : 20220721 20220721160548 ACCESSION NUMBER: 0001209191-22-042841 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220720 FILED AS OF DATE: 20220721 DATE AS OF CHANGE: 20220721 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chacko Jacob CENTRAL INDEX KEY: 0001608936 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39269 FILM NUMBER: 221097119 MAIL ADDRESS: STREET 1: C/O IGNYTA, INC. STREET 2: 11095 FLINTKOTE AVE., SUITE D CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oric Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001796280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 471787157 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 240 E. GRAND AVE. STREET 2: 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 388-5600 MAIL ADDRESS: STREET 1: 240 E. GRAND AVE. STREET 2: 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-07-20 0 0001796280 Oric Pharmaceuticals, Inc. ORIC 0001608936 Chacko Jacob C/O ORIC PHARMACEUTICALS, INC. 240 E. GRAND AVE., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President and CEO Stock Option (right to buy) 16.00 2022-07-20 4 D 0 437500 D 2030-04-22 Common Stock 437500 0 D Stock Option (right to buy) 29.83 2022-07-20 4 D 0 280000 D 2031-01-31 Common Stock 280000 0 D Stock Option (right to buy) 9.48 2022-07-20 4 D 0 300000 D 2032-01-31 Common Stock 300000 0 D Stock Option (right to buy) 4.36 2022-07-20 4 A 0 437500 A 2032-07-19 Common Stock 437500 437500 D Stock Option (right to buy) 4.36 2022-07-20 4 A 0 280000 A 2032-07-19 Common Stock 280000 280000 D Stock Option (right to buy) 4.36 2022-07-20 4 A 0 300000 A 2031-07-19 Common Stock 300000 300000 D Twenty five percent (25%) of the shares subject to the option vested on April 23, 2021, and one forty-eighth (1/48th) of the shares subject to the option vested each month thereafter. On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. Twenty five percent (25%) of the shares subject to the option vested on February 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested each month thereafter. Twenty five percent (25%) of the shares subject to the option would have vested on February 1, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option would have vested each month thereafter. One-third (1/3rd) of the shares subject to the option shall vest on July 20, 2023, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter. Twenty five percent (25%) of the shares subject to the option shall vest on July 20, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. /s/ Christian Kuhlen, attorney-in-fact 2022-07-21